ArticleCureus2026
Dissociated Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Retains Osteoinductive Potential: An In Vivo Proxy for Burst Release.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction This study investigates whether recombinant human bone morphogenetic protein-2 (rhBMP-2), once dissociated from its carrier (absorbable collagen sponge (ACS)) and transported as a soluble factor, retains sufficient osteoinductive capacity to induce ectopic bone formation. Methods ACSs were loaded with rhBMP-2 (1.5 mg/mL) and centrifuged at 500 rcf to generate supernatant run-off (SRO) containing dissociated rhBMP-2. The concentration of rhBMP-2 in the SRO was quantified by UV spectrophotometry (n = 9). In a paired design, 10 athymic nude rats received intermuscular implantation of the centrifuged ACS in the right hindlimb and injection of the corresponding SRO into the contralateral left hindlimb. At 28 days, implant sites were evaluated by micro-CT for bone volume (BV), tissue volume (TV), bone volume fraction (BV/TV), and bone mineral density (BMD), followed by histological assessment. Results In vitro quantification determined that centrifugation released an average of 11.3% ± 6% of the rhBMP-2 load into the SRO. In vivo micro-CT analysis at 28 days demonstrated mineralised tissue formation at both sites. The SRO group exhibited significantly lower total tissue volume than the ACS group (8.05 mm³ vs 29.4 mm³, P < 0.05). No statistically significant differences in bone volume fraction (BV/TV) or bone mineral density (BMD) were detected between groups. Histological evaluation confirmed that mineralised tissue variably represented bone, with the SRO group showing a spectrum from mineralised cartilage to woven bone to corticocancellous-like architecture. The ACS group demonstrated more consistent bone formation but with greater heterogeneity in maturation, including cystic and adipose-dominant phenotypes in some animals. No correlation was observed between the volume of SRO administered and the resulting mineralised tissue volume. Conclusions rhBMP-2 that dissociates from its delivery scaffold retains osteoinductive potential and can induce mineralised tissue when transported as a soluble factor. Histologically, this mineralisation ranged from mineralised cartilage to mature bone. Since clinical burst release substantially exceeds the 11% tested here, these findings represent a conservative estimate of the clinical risk. Liberated rhBMP-2, even in small quantities, may contribute to off-target mineralisation, which could be clinically relevant if formed adjacent to neural elements. These findings emphasise the need for improved controlled-release delivery strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.